| Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis WJ Jansen, R Ossenkoppele, DL Knol, BM Tijms, P Scheltens, ... Jama 313 (19), 1924-1938, 2015 | 1672 | 2015 |
| CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment N Mattsson, H Zetterberg, O Hansson, N Andreasen, L Parnetti, ... Jama 302 (4), 385-393, 2009 | 1478 | 2009 |
| Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts TK Karikari, TA Pascoal, NJ Ashton, S Janelidze, AL Benedet, ... The Lancet Neurology 19 (5), 422-433, 2020 | 1056 | 2020 |
| Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders S Palmqvist, S Janelidze, YT Quiroz, H Zetterberg, F Lopera, E Stomrud, ... Jama 324 (8), 772-781, 2020 | 1040 | 2020 |
| Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia S Janelidze, N Mattsson, S Palmqvist, R Smith, TG Beach, GE Serrano, ... Nature medicine 26 (3), 379-386, 2020 | 1017 | 2020 |
| Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease N Mattsson, U Andreasson, H Zetterberg, K Blennow, ... JAMA neurology 74 (5), 557-566, 2017 | 936 | 2017 |
| Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity S Palmqvist, M Schöll, O Strandberg, N Mattsson, E Stomrud, H Zetterberg, ... Nature communications 8 (1), 1214, 2017 | 802 | 2017 |
| Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers GB Frisoni, M Boccardi, F Barkhof, K Blennow, S Cappa, K Chiotis, ... The Lancet Neurology 16 (8), 661-676, 2017 | 696 | 2017 |
| Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis C Bridel, WN Van Wieringen, H Zetterberg, BM Tijms, CE Teunissen, ... JAMA neurology 76 (9), 1035-1048, 2019 | 668 | 2019 |
| Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease N Mattsson, NC Cullen, U Andreasson, H Zetterberg, K Blennow JAMA neurology 76 (7), 791-799, 2019 | 613 | 2019 |
| Amyloid biomarkers in Alzheimer's disease K Blennow, N Mattsson, M Schöll, O Hansson, H Zetterberg Trends in pharmacological sciences 36 (5), 297-309, 2015 | 567 | 2015 |
| Plasma tau in Alzheimer disease N Mattsson, H Zetterberg, S Janelidze, PS Insel, U Andreasson, ... Neurology 87 (17), 1827-1835, 2016 | 537 | 2016 |
| Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression H Zetterberg, T Skillbäck, N Mattsson, JQ Trojanowski, E Portelius, ... JAMA neurology 73 (1), 60-67, 2016 | 499 | 2016 |
| Smoking and increased Alzheimer's disease risk: a review of potential mechanisms TC Durazzo, N Mattsson, MW Weiner, ... Alzheimer's & Dementia 10, S122-S145, 2014 | 496 | 2014 |
| CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease S Janelidze, H Zetterberg, N Mattsson, S Palmqvist, H Vanderstichele, ... Annals of clinical and translational neurology 3 (3), 154-165, 2016 | 487 | 2016 |
| Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder O Hansson, S Janelidze, S Hall, N Magdalinou, AJ Lees, U Andreasson, ... Neurology 88 (10), 930-937, 2017 | 459 | 2017 |
| The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers N Mattsson, U Andreasson, S Persson, H Arai, SD Batish, S Bernardini, ... Alzheimer's & Dementia 7 (4), 386-395. e6, 2011 | 444 | 2011 |
| Performance of fully automated plasma assays as screening tests for Alzheimer disease–related β-amyloid status S Palmqvist, S Janelidze, E Stomrud, H Zetterberg, J Karl, K Zink, T Bittner, ... JAMA neurology 76 (9), 1060-1069, 2019 | 421 | 2019 |
| Discriminative accuracy of [18F] flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders R Ossenkoppele, GD Rabinovici, R Smith, H Cho, M Schöll, O Strandberg, ... Jama 320 (11), 1151-1162, 2018 | 417 | 2018 |
| CSF biomarker variability in the Alzheimer's Association quality control program N Mattsson, U Andreasson, S Persson, MC Carrillo, S Collins, S Chalbot, ... Alzheimer's & Dementia 9 (3), 251-261, 2013 | 410 | 2013 |
Oskar HanssonProfessor of Neurology, Lund UniversityVerified email at med.lu.se